Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy

Patients with neuroendocrine tumors expressing somatostatin receptors are often treated with 177Lu[Lu]-octreotate. Despite being highly effective in animal models, 177Lu[Lu]-octreotate-based therapies in the clinical setting can be optimized further. The aims of the study were to identify and elucidate possible optimization venues for 177Lu[Lu]-octreotate tumor therapy by characterizing transcriptional responses in the GOT1 small intestine neuroendocrine tumor model in nude mice.

Source: Nuclear Medicine and Biology - February 6, 2018 Category: Nuclear Medicine Authors: Johan Spetz, Nils Rudqvist, Britta Langen, Toshima Z. Parris, Johanna Dalmo, Emil Sch üler, Bo Wängberg, Ola Nilsson, Khalil Helou, Eva Forssell-Aronsson Source Type: research